Jeff Sharman, CLL expert, discusses what's hot in CLL. He explains how we are leaving a generation of chemotherapy, transferring into a new area of targeted therapies. While FCR continues to be a treatment option, Dr. Sharman believes its day is passing as targeted therapies continue to progress. The key question remains how to decide what targeted therapy to use when. While the long term side effects of the targeted therapies are unknown, the hope is a decrease in toxicty with an increase of efficacy.